Illuminare Biotechnologies secures Series B funding to advance its biotechnology initiatives. The company also appoints a new CEO to lead its growth and operational strategy.
Illuminare Biotechnologies names **Brian Longstreet** as its new Chief Executive Officer. He will oversee the company’s **Phase 2/3 clinical development** and commercialization efforts. Longstreet brings extensive experience in biopharmaceutical leadership to guide Illuminare’s pipeline forward.
Illuminare Biotechnologies develops a myelin-binding fluorophore that illuminates nerves during surgery. The technology aids surgeons in visualizing nerves more clearly, potentially reducing surgical harm. The approach leverages fluorescent imaging to enhance precision in delicate procedures.
Researchers are testing **Illuminare-1**, a fluorophore, to determine a safe and effective dose for use in prostate cancer surgeries. The goal is to evaluate its potential in reducing surgical complications during future clinical studies. The compound is being assessed for its feasibility in improving precision during cancer care procedures.
